Equillium's partner biocon initiates phase 2 study of itolizumab in ulcerative colitis

La jolla, calif.--( business wire )--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that biocon limited, in collaboration with equillium, has initiated a phase 2 clinical study of itolizumab in patients with ulcerative colitis (uc).
EQ Ratings Summary
EQ Quant Ranking